医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

INJEX Pharma AG Obtains Chinese SFDA Registration for INJEX30 Needle Free Injection System

2013年04月16日 PM06:25
このエントリーをはてなブックマークに追加


 

BEIJING

INJEX Pharma AG is pleased to announce that yesterday its wholly owned subsidiary INJEX Pharma GmbH has successfully registered the INJEX30 needle free injection system with the Chinese State Food and Drug Administration (SFDA), supported by its exclusive distributor Hangzhou Hema Medical Equipment Co. Ltd. The SFDA is responsible for regulating the market access of medical devices in the People’s Republic of China. The arduous approval process took more than 1.5 years and has required a detailed documentation.

The registration is a significant milestone in the Company’s efforts to expand its offerings in key markets. One area of application is the use of insulin for persons with diabetes. According to figures in the recent Diabetes Atlas (5th edition, 2012) published by the International Diabetes Federation, about one fourth of the 371 million people with diabetes live in China. Hangzhou Hema Medical Equipment can immediately start marketing the INJEX30 system.

For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com.

INJEX Pharma AG:

INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the medical technology segment and in the cosmetics and beauty markets. The Group’s core business areas are the needle-free INJEX30 system and the product line SHIREEN in the beauty market. The main markets of the Group are North America, China, India, Russia and Europe.

Language:     English
Company: INJEX Pharma AG
Buckower Damm 114

12349 Berlin

Germany
Phone: +49 89 24 41 18 – 223
Fax: +49 89 24 41 18 – 499
E-mail:

ir@injex.de

Internet:

www.injex.de

ISIN: DE000A0STYL7
WKN: A0STYL
Listed: Regulierter Markt in Frankfurt (General Standard) Notierung im Regulierten Markt vorgesehen / intended to be listed at Regulated Market

CONTACT

INJEX Pharma AG
Investor Relations Team
Philipp Bruns
t:
+49 89 24 41 18 – 223
f: +49 89 24 41 18 – 499
ir@injex.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作
  • ベルタンとザイモリサーチが新しい連携を発表
  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin